Stockscreener 앱 받기
0.55
3.48%
0.0185
시간 외 거래:
.57
0.02
+3.64%
전일 마감가:
$0.5315
열려 있는:
$0.531
하루 거래량:
697.00K
Relative Volume:
0.96
시가총액:
$32.30M
수익:
-
순이익/손실:
$-39.35M
주가수익비율:
-0.1536
EPS:
-3.58
순현금흐름:
$-48.92M
1주 성능:
-17.91%
1개월 성능:
-4.48%
6개월 성능:
-84.76%
1년 성능:
+10.00%
1일 변동 폭
$0.5221
$0.5565
1주일 범위
$0.5221
$0.7034
52주 변동 폭
$0.4401
$5.8299
Elevation Oncology Inc Stock (ELEV) Company Profile
명칭
Elevation Oncology Inc
전화
(716) 371-1125
주소
101 FEDERAL STREET, BOSTON
ELEV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ELEV | 0.55 | 32.30M | 0 | -39.35M | -48.92M | -3.58 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-23 | 개시 | H.C. Wainwright | Buy |
Elevation Oncology Inc 주식(ELEV)의 최신 뉴스
Logos Global Management LP Adjusts Stake in Elevation Oncology I - GuruFocus.com
OrbiMed Advisors LLC Increases Stake in Elevation Oncology Inc - GuruFocus.com
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readout - Investing.com
Elevation Oncology’s Q3 2024 Highlights and Financial Report - TipRanks
Goldman Sachs Group Inc's Strategic Acquisition in Elevation Onc - GuruFocus.com
Elevation Oncology's Cancer Drug Shows 43% Response Rate, Secures FDA Fast Track | ELEV Stock News - StockTitan
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements - PR Newswire
Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - MSN
Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News
Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex
It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News
Elevation Oncology Inc (ELEV)’s stock price range in the last year - US Post News
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock - MSN
Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance
In the Green: Elevation Oncology Inc (ELEV) Closes at 0.52, Up/Down -3.69 from Previous Day - The Dwinnex
Taking on analysts’ expectations and winning: Elevation Oncology Inc (ELEV) - SETE News
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Market Momentum Report: Elevation Oncology Inc (ELEV)’s Positive Close at 0.59 - The Dwinnex
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readouts - Investing.com
Should investors be concerned about Elevation Oncology Inc (ELEV)? - US Post News
Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Elevance Health Inc [ELV] PERU RAMIRO G sells 753 Shares for $0.4 million - Knox Daily
Check out these key findings about Elevation Oncology Inc (ELEV) - SETE News
Lombard Odier Asset Management Europe Ltd Invests $2.51 Million in Elevance Health, Inc. (NYSE:ELV) - Defense World
FDA grants fast track designation for Elevation Oncology’s EO-3021 - Pharmaceutical Business Review
Pacer Advisors Inc. Decreases Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Distillate Capital Partners LLC Grows Position in Elevance Health, Inc. (NYSE:ELV) - MarketBeat
Study Underscores Importance of Medicaid Coverage for Pregnant Women - Healthcare Innovation
Elevai Labs shares tumble on pricing of new stock offering - The Business Journals
Elevance Health, Inc. (NYSE:ELV) Position Boosted by Magnetar Financial LLC - Defense World
Decoding Elevance Health's Options Activity: What's the Big Picture? - Benzinga
ELAB’s price-to-free cash flow ratio: What it means for investors - US Post News
Ratios in Focus: Analyzing Elevation Oncology Inc (ELEV)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Why Elevai Labs (ELAB) Stock Is Down 60% Today - Benzinga
Investing in Elevation Oncology Inc (ELEV) might be a great opportunity, but the stock is a bit undervalued - US Post News
Baltic Fintech Eleving To Raise Up To €30M In IPO - Law360
FDA grants fast track to Elevation Oncology's cancer drug - Investing.com
Ensign Peak Advisors Inc Acquires 2,862 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering - GlobeNewswire
Elevation Oncology Gets FDA Fast-Track Designation for EO-3021 - MarketWatch
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - StockTitan
Eleving Group Targets $34 Million From Initial Public Offering - MarketWatch
Fidelis Capital Partners LLC Acquires 1,168 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
1832 Asset Management L.P. Sells 5,622 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Frank Rimerman Advisors LLC Raises Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevation Oncology Inc (ELEV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):